Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG
Article in Pharmaceutics (March 2023)
The most recent citing publications are shown below. View all 31 publications that cite this research output on Dimensions.
Chapter 33 Inactivated and Recombinant Influenza Vaccines
Book chapter (January 2023)
Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines
Article in Vaccines (October 2020)